Svitlana Igel

463 total citations
15 papers, 303 citations indexed

About

Svitlana Igel is a scholar working on Pharmacology, Oncology and Pediatrics, Perinatology and Child Health. According to data from OpenAlex, Svitlana Igel has authored 15 papers receiving a total of 303 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Pharmacology, 7 papers in Oncology and 5 papers in Pediatrics, Perinatology and Child Health. Recurrent topics in Svitlana Igel's work include Pharmacogenetics and Drug Metabolism (9 papers), Estrogen and related hormone effects (4 papers) and Drug Transport and Resistance Mechanisms (3 papers). Svitlana Igel is often cited by papers focused on Pharmacogenetics and Drug Metabolism (9 papers), Estrogen and related hormone effects (4 papers) and Drug Transport and Resistance Mechanisms (3 papers). Svitlana Igel collaborates with scholars based in Germany, United States and Switzerland. Svitlana Igel's co-authors include Matthias Schwab, Elke Schaeffeler, Simon U. Jaeger, Jun J. Yang, Laura Hinze, Martin Stanulla, Ute Hofmann, Heike Tegude, Michel Eichelbaum and Stefanie S. Brenner and has published in prestigious journals such as Clinical Cancer Research, Human Molecular Genetics and Clinical Pharmacology & Therapeutics.

In The Last Decade

Svitlana Igel

14 papers receiving 294 citations

Peers

Svitlana Igel

PPCH

ONCOL

PHEOH

PHARM

Patrick Mayo Canada

Hyewon Chung South Korea

Chantal Barin‐Le Guellec France

Pauline Bosco‐Lévy France

Hoi Y. Tong Spain

Dongseong Shin South Korea

Bani Tamraz United States

Jina Jung South Korea

Youssef M. Roman United States

Nils Tore Vethe Norway

Patrick Mayo Canada

Svitlana Igel

79 ×0.9

PPCH

60 ×0.7

ONCOL

43 ×0.7

PHEOH

79 ×1.2

PHARM

91 ×2.0

Citations per year, relative to Svitlana Igel Svitlana Igel (= 1×) peers Patrick Mayo

Countries citing papers authored by Svitlana Igel

Since Specialization

Citations

This map shows the geographic impact of Svitlana Igel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Svitlana Igel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Svitlana Igel more than expected).

Fields of papers citing papers by Svitlana Igel

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Svitlana Igel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Svitlana Igel. The network helps show where Svitlana Igel may publish in the future.

Co-authorship network of co-authors of Svitlana Igel

This figure shows the co-authorship network connecting the top 25 collaborators of Svitlana Igel. A scholar is included among the top collaborators of Svitlana Igel based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Svitlana Igel. Svitlana Igel is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

15 of 15 papers shown

Mürdter, Thomas E., Werner Schroth, Matthew P. Goetz, et al.. (2025). Supplementation of Tamoxifen with Low-Dose Endoxifen in Patients with Breast Cancer with Impaired Tamoxifen Metabolism (TAMENDOX): A Randomized Controlled Phase I/II Trial. Clinical Cancer Research. 31(23). 4903–4911.

Selzer, Dominik, Thomas E. Mürdter, Svitlana Igel, et al.. (2022). Physiologically Based Pharmacokinetic Modeling to Describe the CYP2D6 Activity Score-Dependent Metabolism of Paroxetine, Atomoxetine and Risperidone. Pharmaceutics. 14(8). 1734–1734. 8 indexed citations

Selzer, Dominik, Svitlana Igel, Reinhold Kerb, et al.. (2022). Prediction of Drug–Drug–Gene Interaction Scenarios of (E)-Clomiphene and Its Metabolites Using Physiologically Based Pharmacokinetic Modeling. Pharmaceutics. 14(12). 2604–2604. 2 indexed citations

Heinkele, Georg, et al.. (2020). Stereoselective quantification of phase 1 and 2 metabolites of clomiphene in human plasma and urine. Talanta. 221. 121658–121658. 7 indexed citations

Just, Katja S., Harald Dormann, Marlen Schurig, et al.. (2020). The phenotype of adverse drug effects: Do emergency visits due to adverse drug reactions look different in older people? Results from the ADRED study. British Journal of Clinical Pharmacology. 86(11). 2144–2154. 15 indexed citations

Weigl, Korbinian, Kaja Tikk, Michael Hoffmeister, et al.. (2019). Prevalence of a First-Degree Relative With Colorectal Cancer and Uptake of Screening Among Persons 40 to 54 Years Old. Clinical Gastroenterology and Hepatology. 18(11). 2535–2543.e3. 11 indexed citations

Just, Katja S., Harald Dormann, Marlen Schurig, et al.. (2019). Personalising drug safety—results from the multi-centre prospective observational study on Adverse Drug Reactions in Emergency Departments (ADRED). European Journal of Clinical Pharmacology. 76(3). 439–448. 17 indexed citations

Schaeffeler, Elke, Simon U. Jaeger, Jun J. Yang, et al.. (2019). Impact of NUDT15 genetics on severe thiopurine-related hematotoxicity in patients with European ancestry. Genetics in Medicine. 21(9). 2145–2150. 74 indexed citations

Tikk, Kaja, Korbinian Weigl, Michael Hoffmeister, et al.. (2018). Study protocol of the RaPS study: novel risk adapted prevention strategies for people with a family history of colorectal cancer. BMC Cancer. 18(1). 720–720. 7 indexed citations

10.

Krauß, Markus, Ute Hofmann, Clemens Schafmayer, et al.. (2017). Translational learning from clinical studies predicts drug pharmacokinetics across patient populations. npj Systems Biology and Applications. 3(1). 11–11. 12 indexed citations

11.

Mürdter, Thomas E., Reinhold Kerb, Miia Turpeinen, et al.. (2011). Genetic polymorphism of cytochrome P450 2D6 determines oestrogen receptor activity of the major infertility drug clomiphene via its active metabolites. Human Molecular Genetics. 21(5). 1145–1154. 33 indexed citations

12.

Burk, Oliver, Stefanie S. Brenner, Ute Hofmann, et al.. (2010). The Impact of Thyroid Disease on the Regulation, Expression, and Function of ABCB1 (MDR1/P Glycoprotein) and Consequences for the Disposition of Digoxin. Clinical Pharmacology & Therapeutics. 88(5). 685–694. 19 indexed citations

13.

Hofmann, Ute, Andreas Busjahn, G Franke, et al.. (2009). Genetic Influences on the Pharmacokinetics of Orally and Intravenously Administered Digoxin as Exhibited by Monozygotic Twins. Clinical Pharmacology & Therapeutics. 86(6). 605–608. 12 indexed citations

14.

Igel, Svitlana, Siegfried Drescher, Ute Hofmann, et al.. (2007). Increased??Absorption??of??Digoxin from??the??Human??Jejunum Due??to??Inhibition??of??Intestinal Transporter-Mediated Efflux. Clinical Pharmacokinetics. 46(9). 777–785. 56 indexed citations

15.

Fux, Richard, Doris Kloor, Marina Hermes, et al.. (2005). Effect of acute hyperhomocysteinemia on methylation potential of erythrocytes and on DNA methylation of lymphocytes in healthy male volunteers. American Journal of Physiology-Renal Physiology. 289(4). F786–F792. 30 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact